{"id":989707,"date":"2026-05-28T07:27:37","date_gmt":"2026-05-28T07:27:37","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/989707\/"},"modified":"2026-05-28T07:27:37","modified_gmt":"2026-05-28T07:27:37","slug":"new-treatment-could-reverse-osteoarthritis-within-weeks","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/989707\/","title":{"rendered":"New Treatment Could Reverse Osteoarthritis Within Weeks"},"content":{"rendered":"

\"Knee<\/a>Researchers have developed experimental osteoarthritis therapies that appear to trigger damaged joints to heal themselves in animal studies. The approaches, which include a regenerative injection and a biomaterial repair system, could point toward a future where joint degeneration is treated by restoring tissue rather than replacing it. Credit: Shutterstock<\/p>\n

Experimental osteoarthritis therapies repaired damaged joints in animals and may enter clinical trials within 18 months.<\/strong><\/p>\n

A new experimental treatment may one day allow arthritic joints to heal themselves \u2014 without major surgery. In animal studies, researchers successfully regenerated damaged cartilage and restored aging joints to a healthy state within just weeks.<\/p>\n

The breakthrough therapies include a single regenerative injection that delivers healing bursts of medicine over time and a biomaterial repair system designed to recruit the body\u2019s own cells to rebuild damaged cartilage and bone.<\/p>\n

The findings were promising enough that the Advanced Research Projects Agency for Health (ARPA-H) announced that the research will advance to the next phase of a project worth up to $33.5 million. The effort is part of ARPA-H\u2019s Novel Innovations for Tissue Regeneration in Osteoarthritis (NITRO) program, led by Dr. Ross Uhrich.<\/p>\n

The multidisciplinary team behind the work includes scientists and engineers from the University of Colorado Boulder, CU Anschutz, and Colorado State University.<\/p>\n

\u201cIn two years, we were able to go from a moonshot idea to developing these therapies to demonstrating that they reverse osteoarthritis in animals,\u201d said principal investigator Stephanie Bryant, professor of chemical and biological engineering at CU Boulder. \u201cOur goal is not just to treat pain and halt progression, but to end this disease.\u201d<\/p>\n

\"StephanieStephanie Bryant works with Laurel Stefani, a biomedical engineering PhD candidate from Richardson, TX. Credit: Casey Cass\/CU BoulderOsteoarthritis Treatment Limitations Drive New Approaches<\/p>\n

Osteoarthritis is the third most common disease in the United States and affects about one in six people over age 30 worldwide. The condition breaks down cartilage, the protective tissue that prevents bones from rubbing together. As the disease progresses, it can also damage bone, alter joint structure, and make movement extremely painful.<\/p>\n

Current treatment options are limited mainly to pain management or joint replacement surgery. There is no cure, so the Colorado researchers are pursuing two new strategies.<\/p>\n

\"StephanieStephanie Bryant, professor of chemical and biological engineering, in her lab at the BioFrontiers Institute at CU Boulder. Credit: Casey Cass\/CU Boulder<\/p>\n

One approach uses an existing FDA-approved drug that has been adapted for osteoarthritis treatment. Bryant and her team created a patented particle delivery system that can be injected directly into a joint and slowly release the medication over several months.<\/p>\n

For patients with major cartilage or bone damage, the researchers also developed engineered proteins that can be delivered arthroscopically and hardened in place. The material attracts the body\u2019s progenitor cells to repair the damaged area.<\/p>\n

Animal Studies Reveal Rapid Joint Repair<\/p>\n

In animal studies, arthritic and injured joints treated with the injection returned to a healthy state within four to eight weeks. When researchers repaired holes in bone or cartilage, they observed what Bryant described as \u201cfull regeneration and repair of the defect.\u201d The therapies also showed strong regenerative effects in human cells taken from patients undergoing joint replacement surgery.<\/p>\n

NITRO was the first ARPA-H program and was created to develop \u201cminimally invasive therapeutics that fully regenerate damaged joints.\u201d Two years ago, the program awarded the Colorado team up to $33.5 million based on milestone achievements.<\/p>\n

After successfully completing phase one, the researchers are now moving into phase two.<\/p>\n

\u201cIt\u2019s super exciting to be a part of the very first program of ARPA-H and to be one of the first teams to advance to the second phase,\u201d said Bryant.<\/p>\n

\"StephaniePrincipal Investigator Stephanie Bryant in the lab with a student at the BioFrontiers Institute at the University of Colorado Boulder. Credit: Casey Cass\/CU BoulderResearchers Envision Affordable Regenerative Care<\/p>\n

Dr. Evalina Burger, professor and chair of the Department of Orthopedics at CU Anschutz, said osteoarthritis affects a wide range of patients, from older adults struggling with everyday activities to athletes forced to leave sports because of chronic joint pain.<\/p>\n

\u201cAt the moment, the options for many patients are either a massive, expensive surgery or nothing. There\u2019s not a lot in between,\u201d said Burger, who has been following the team\u2019s research with interest. \u201cThat\u2019s why ARPA-H is so important.\u201d<\/p>\n

Burger and Bryant hope the treatments could eventually offer patients in the early stages of osteoarthritis a low-cost, single-dose therapy that keeps joints healthy for years. Patients with tissue damage could potentially receive treatment during a single doctor visit followed by a quick recovery.<\/p>\n

The team plans to publish the animal study results in a peer-reviewed journal later this year. The researchers have also launched Renovare Therapeutics Inc. to help commercialize the technology.<\/p>\n

Clinical Trials Could Begin Within 18 Months<\/p>\n

If future studies continue to show positive results, Bryant said clinical trials could begin in as little as 18 months.<\/p>\n

\u201cThis could be a real game-changer for patients,\u201d said Bryant.<\/p>\n

Never miss a breakthrough: Join the SciTechDaily newsletter.<\/a><\/b>
Follow us on Google<\/a> and Google News<\/a>.<\/b><\/p>\n","protected":false},"excerpt":{"rendered":"Researchers have developed experimental osteoarthritis therapies that appear to trigger damaged joints to heal themselves in animal studies.…\n","protected":false},"author":2,"featured_media":989708,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[11],"tags":[2346,25820,41531,105,98730,16,15,133026],"class_list":["post-989707","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health","tag-arthritis","tag-biomedical-engineering","tag-bones","tag-health","tag-regenerative-medicine","tag-uk","tag-united-kingdom","tag-university-of-colorado-at-boulder"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/116651023983237849","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/989707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=989707"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/989707\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/989708"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=989707"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=989707"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=989707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}